Indication
RPE65 Mutation-associated Retinal Dystrophy
1 clinical trial
4 products
Product
AAV2-hRPE65v2Clinical trial
A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in USStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Product
voretigene neparvovec-rzyl